Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 12/20 | 0.70 |
| ▸ | DBF4 | Q9UBU7 | 12/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28295520 | 0.85 | CDC7 (0.64) | CDC7DBF4LMNAKDM4EALDH1A1 | |
| SCHEMBL5733147 | 0.82 | CDC7 (1.00) | CDC7DBF4LMNAKDM4EALDH1A1 | |
| SCHEMBL1984283 | 0.82 | CDC7 (0.64) | CDC7DBF4LMNAKDM4EALDH1A1 | |
| SCHEMBL289996 | 0.81 | CDC7 (0.65) | CDC7DBF4LMNAKDM4EALDH1A1 | |
| SCHEMBL2881465 | 0.81 | CDC7 (0.72) | CDC7DBF4LMNAKDM4EALDH1A1 | |
| SCHEMBL28295522 | 0.80 | CDC7 (0.67) | CDC7DBF4LMNAKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6201525 | 0.80 | CDC7 (0.70) | CDC7DBF4LMNAKDM4EALDH1A1 | |
| SCHEMBL892889 | 0.79 | CDC7 (0.77) | CDC7DBF4LMNAKDM4EALDH1A1 | |
| SCHEMBL12186978 | 0.78 | CDC7 (0.64) | CDC7DBF4LMNAKDM4EALDH1A1 | |
| SCHEMBL290384 | 0.77 | CDC7 (0.75) | CDC7DBF4LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2338887-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, PON1, CBR1 | CDC7 3107/4885DBF4 3228/4885LMNA 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.